Transient elastography: A non-invasive tool for assessing liver fibrosis in HIV/HCV patients

doi:10.3748/wjg.v16.i41.5225

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3546)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

326

HTML

2912

Figures (1-1)

150

Tables (1-6)

158

Sum=3546

Nov 7, 2010 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 7, 2010; 16(41): 5225-5232
Published online Nov 7, 2010. doi: 10.3748/wjg.v16.i41.5225

Table 1 Demographic characteristics of the study populations (mean ± SD) n (%)

	HIV (n = 71)	HCV (n = 53)	HIV/HCV (n = 66)
Age (yr)	43.3 ± 10.3^a	49.7 ± 12.5	45.6 ± 12.5
Male gender	50 (70)	36 (67.9)	49 (74.2)
BMI (kg/m²)	23.6 ± 3.4^a	26.0 ± 3.6	22.8 ± 3.0^b
Risk group
Transfusion	-	17 (32.1)	4 (6.1)^b
Homosexual men	21 (29.5)	-	1 (1.5)
Intravenous drug use	4 (5.6)	7 (13.2)^c	41 (62.1)
Others	-	12 (22.6)	-
Unknown	9 (12.6)	16 (30.2)	8 (12.1)
HCV genotype 3:non3	-	7:46^d	20:46
HAART	57 (80.2)	-	60 (90.9)
Alcohol	6 (8.4)	4 (7.5)	5 (7.5)
Diabetes + IFG	2 (2.8)	4 (7.5)^e	11 (16.6)

^aP < 0.002,

^bP < 0.0001 vs hepatitis C virus (HCV);

^cP < 0.0001,

^dP < 0.03,

^eP < 0.001 vs human immunodeficiency virus (HIV)/HCV. IFG: Impaired fasting glucose; BMI: Body mass index; HAART: Highly active anti-retroviral therapy.

Table 2 Main hematological and virological parameters in the three study groups (mean ± SD)

	HIV (n = 71)	HCV (n = 53)	HIV/HCV (n = 66)
AST/ALT	1 ± 0.4	0.72 ± 0.28^a^j	0.9 ± 0.4
ALT (U/L), mean (range)	22 (7-113)^f^h	75 (16-551)	56.5 (9-280)^g
AST (U/L), mean (range)	21 (11-56)^f^h	52.5 (18-209)	42.5 (14-281)
γGT (IU/L), mean (range)	33 (9-461)^h	40.5 (10-479)ⁱ	76.5 (11-479)
Mean platelet count (10⁹/L)	208 ± 59	184 ± 60	173 ± 61^b
T-Chol (mg/dL)	201 ± 46	175 ± 28^d	171 ± 48^c
HDL-Chol (mg/dL)	44 ± 16	47 ± 12	44 ± 15
LDL Chol (mg/dL)	123 ± 32	108 ± 37.5	97 ± 40^a
TG (mg/dL), mean (range)	137 (36-615)	103 (32-354)^e^j	118 (49-614)
HCV-RNA (IU/mL) > 700.000	-	29 (54.7)	44 (66.6)
HIV-RNA (copies/mL), mean (range)	6050 (50-700 000)	-	3300 (60-1 100 000)
HIV-RNA < 47 copies/mL (%)	44 (62)		45 (68.1)
CD4+ count (cells/μL), mean (range)	466.5 (17-1282)	-	446 (35-1445)
CD4+ < 200 cells/μL	38¹	-	38²

^aP < 0.0001,

^bP < 0.002,

^cP < 0.001,

^dP < 0.004,

^eP < 0.02 vs human immunodeficiency virus (HIV);

^fP < 0.0001,

^gP < 0.02 vs hepatitis C virus (HCV);

^hP < 0.0001,

ⁱP < 0.01,

^jP < 0.05 vs HIV/HCV.

¹Data available in 66 patients;

²Data available in 56 patients. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: γ-glutamyl transferase; T-Chol: Total cholesterol; HDL: High density lipoprotein; LDL: Low density lipoprotein; TG: Triglyceride.

Table 3 Estimates of liver fibrosis using transient elastography in the study population n (%)

LS	Metavir	HIV (n = 71)	HCV (n = 53)	HIV/HCV (n = 57)
< 7.1	F0-F1	56 (78.8)	23 (43.4)	19 (33.3)
7.1-9.4	F2	11 (15.4)	15 (28.3)	9 (15.8)
9.5-12.4	F3	1 (1.4)	4 (7.5)	9 (15.8)
≥ 12.5	F4	3 (4.2)	11 (20.7)	20 (35.1)	χ²_MH = 4, P < 0.04
≥ F3		4 (5.6)	15 (28.3)	29 (50.9)	χ² = 5, P < 0.03

HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; LS: Liver stiffness.

Table 4 Estimates of liver fibrosis using biochemical markers and transient elastography, mean (range)

	HIV (n = 71)	HCV (n = 53)	HIV/HCV (n = 57)
APRI	0.31 (0.1-1.6)^a^b	0.93 (0.28-6.07)	0.92 (0.17-19.7)
FIB-4	0.93 (0.39-4.28)^a	1.62 (0.47-12.6)	1.63 (0.63-23.8)
LS	5.4 (3.2-26.6)^a^b	7.3 (3.4-40.9)^c	9.8 (4.3-48.8)

^aP < 0.0001 vs hepatitis C virus (HCV);

^bP < 0.0001,

^cP < 0.05 vs human immunodeficiency virus (HIV)/HCV. LS: Liver stiffness; APRI: Aspartate aminotransferase platelet ratio index.

Table 5 Correlation between liver stiffness and aminotransferase platelet ratio index/FIB-4 values according to the liver stiffness cut-offs

	LS < 7.1 kPa (n = 98)		LS (7.1-9.4 kPa) (n = 35)		LS≥9.5 kPa (n = 48)
	r	P	r	P	r	P
APRI	0.01	NS	0.23	NS	0.50	< 0.0001
FIB-4	0.01	NS	0.25	NS	0.53	< 0.0001

APRI: Aminotransferase platelet ratio index; LS: Liver stiffness; NS: Not significant.

Table 6 Correlation (r or ρ) between liver stiffness and studied parameters

	LS
	HIV	HCV	HIV/HCV
BMI	0.11	-0.1	0.02
HCV genotype 3/non 3	-	-0.1	-0.26
HCV-RNA	-	-	-0.26
HIV-RNA	0.21	-	0.18
Time HAART	-0.047	-	0.09
CD4 cells count	0.074	-	-0.32^d
Alcohol	-0.096	0.70^a	0.30^e
T-Chol	-0.09	-0.32^b	-0.18
TG	0.06	0.18	0.1
HDL-Chol	-0.1	0.05	-0.16
Diabetes + IFG	-0.01	0.19	0.14
Time HCV	-	0.24	-0.02
ALT	0.03	0.1	0.23
AST	0.18	0.56^c	0.40^a
Platelets	-0.02	-0.56^c	-0.61^c
APRI score	0.04	0.70^c	0.50^c
FIB-4 score	0.06	0.75^c	0.60^c

LS: Liver stiffness; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; BMI: Body mass index; HAART: Highly active anti-retroviral therapy; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; T-Chol: Total cholesterol; HDL: High density lipoprotein; TG: Triglyceride; IFG: Impaired fasting glucose; APRI: Aminotransferase platelet ratio index.

^aP < 0.001;

^bP < 0.03;

^cP < 0.0001;

^dP < 0.02;

^eP < 0.04.

Citation: Li Vecchi V, Soresi M, Colomba C, Mazzola G, Colletti P, Mineo M, Di Carlo P, La Spada E, Vizzini G, Montalto G. Transient elastography: A non-invasive tool for assessing liver fibrosis in HIV/HCV patients. World J Gastroenterol 2010; 16(41): 5225-5232
URL: https://www.wjgnet.com/1007-9327/full/v16/i41/5225.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i41.5225